Copyright
©The Author(s) 2021.
World J Gastrointest Oncol. Dec 15, 2021; 13(12): 1880-1895
Published online Dec 15, 2021. doi: 10.4251/wjgo.v13.i12.1880
Published online Dec 15, 2021. doi: 10.4251/wjgo.v13.i12.1880
Guidelines | Indications | Investigations | Algorithm of follow-up |
IAP (2006) | BD-IPMNs ≤ 30 mm; Without: Symptoms, mural nodules, positive cytology | MRI/MRCP or CT | Size ≤ 20 mm: every 6-12 mo; Size 20-30 mm: every 3-6 mo; The interval can be longer after 2 yr without changes |
AGA (2015) | BD-IPMNs ≤ 30 mm; Without: Solid component, dilated MPD, HGD/cancer | MRI | Years 1, 2, 5 from initial diagnosis; It can be considered to discontinue; If there is no changes after years |
IAP (2017) | No HRS/WF | MRI/MRCP, CT | Size < 10 mm: At 6 mo from diagnosis every 2 yr (if no change) |
No HRS/WF | MRI/MRCP, CT | Size 10-20 mm: At 6 mo from diagnosis yearly per 2 yr | |
No HRS/WF | MRI/MRCP, EUS | Size 20-30 mm: EUS in 3-6 mo, yearly EUS or MRI | |
No HRS, WF present and size < 30 mm | MRI/MRCPEUS | Every 3-6 mo EUS or MRI | |
European (2018) | No AI | MRI/MRCP or EUS, CA 19.9 | Every 6 mo for the first year; Yearly after first year |
No AI, 1 RI in patient, with comorbidities | MRI/MRCP or EUS, CA 19.9 | Every 6 mo |
- Citation: Jabłońska B, Szmigiel P, Mrowiec S. Pancreatic intraductal papillary mucinous neoplasms: Current diagnosis and management. World J Gastrointest Oncol 2021; 13(12): 1880-1895
- URL: https://www.wjgnet.com/1948-5204/full/v13/i12/1880.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v13.i12.1880